Durata starts ABSSSI drug Phase 3 trial
The trial is planned to investigate the safety and efficacy of dalbavancin to vancomycin, with patients randomized to vancomycin allowed to switch to oral linezolid after three days
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.
Study of V-101 is a randomized, multi-centered, double-blinded, vehicle-controlled, Phase II clinical trial designed to evaluate the dose-response relationship of two concentrations of V-101 cream vs. vehicle (placebo).